Welcome to our dedicated page for Azenta SEC filings (Ticker: AZTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Azenta, Inc.'s SEC filings document operating results, material events, governance matters and acquisition agreements for a life sciences solutions company built around cold-chain sample management and multiomics services. Recent Form 8-K disclosures include quarterly results and financial-condition updates, leadership and board changes, and the material definitive agreement under which Azenta UK Ltd acquired UK Biocentre.
The company’s proxy and annual-meeting filings describe director elections, advisory executive-compensation votes, equity incentive plan amendments and auditor ratification. Together with material-event reports, these filings provide formal disclosure on Azenta’s governance structure, capital-related authorizations, transaction terms and recurring public-company reporting obligations.
Azenta, Inc. (AZTA) reported that Erik J. Bello, who serves as Vice President and Chief Accounting Officer, has filed an initial insider ownership report on Form 3. The filing states in its remarks that no securities are beneficially owned by this reporting person and lists no transactions or holdings.
Azenta, Inc. (AZTA) reports that Thelema S.à r.l. has repaid in full the secured vendor loan connected to the sale of B Medical Systems S.à r.l. Azenta Germany GmbH had provided this vendor loan in a principal amount of USD 35,000,000 as part of the USD 63,000,000 purchase price.
The loan, bearing 6.0% annual interest and maturing three months after funding, was secured by a pledge over 100% of B Medical’s equity. On September 3, 2026, Thelema repaid USD 35,373,333, covering principal and accrued interest, terminating the Vendor Loan Agreement and releasing the share pledge. Azenta has now received the entire USD 63,000,000 purchase price in cash, eliminating credit exposure from this divestiture and supporting its stated capital allocation strategy.
Azenta, Inc. (AZTA) reported a leadership transition and guidance update. On August 22, 2026, John P. Marotta resigned as President, Chief Executive Officer and director, with the board stating his resignation was not due to any disagreement on operations, policies or practices, and reduced its size from nine to eight members.
The board appointed director Dr. Martin D. Madaus as Interim President and CEO and principal executive officer, and he will remain on the board while stepping down from the Nominating and Governance Committee. Azenta reaffirmed its previously issued fourth quarter fiscal 2026 total revenue guidance, but now expects adjusted EBITDA to reflect an approximately $3 million one-time consulting expense in that quarter; excluding this charge, the company would also be reaffirming adjusted EBITDA.
Azenta, Inc. senior vice president and chief human resources officer Olga Pirogova reported a Form 4 transaction involving company common stock. On August 9, 2026, 1,085 shares were withheld by the company at $32.04 per share to satisfy tax withholding obligations upon vesting of equity awards, leaving her with 31,953 shares held directly. The company notes this was not a market sale of securities.
Azenta, Inc. appointed Erik J. Bello, age 51, as Vice President, Chief Accounting Officer, expected to start on August 31, 2026. He will serve as the company’s principal accounting officer, while Lawrence Lin will continue as Executive Vice President and Chief Financial Officer and as principal financial officer.
Bello’s background includes senior accounting roles at Onto Innovation Inc., UniFirst Corporation, and other organizations, and he is a certified public accountant. Under a July 30, 2026 offer letter, he will receive a $380,000 annual base salary, a one-time $80,000 sign-on bonus subject to repayment if he resigns within one year, and eligibility for an annual incentive equal to 50% of base salary. He will receive long-term incentive awards valued at $150,000 for the current fiscal year in time-based RSUs and $300,000 for the following fiscal year, split between time-based RSUs and performance share units.
Azenta, Inc. reported third‑quarter 2026 revenue from continuing operations of 161,178 (in thousands), up from 143,855, producing gross profit of 72,356. Higher operating costs led to an operating loss of 4,178 and a loss from continuing operations of 1,529, while discontinued operations contributed income of 3,985, resulting in net income of 2,456.
For the nine months ended June 30, 2026, revenue was 454,615 (in thousands) and a non‑cash goodwill impairment of 149,083 drove a loss from continuing operations of 163,740 and a total net loss of 173,774. Total assets were 1,876,211, including cash and cash equivalents of 189,654 and marketable securities of 332,230, with stockholders’ equity of 1,510,129.
Azenta completed the sale of its B Medical Systems business for $63.0 million, including a $35.0 million secured Vendor Loan Agreement at 6.0% interest, and acquired UK Biocentre for approximately $27.5 million to expand sample management services. It repurchased 2.3 million shares for $50.0 million under a $250.0 million authorization and reduced a legacy semiconductor divestiture loss contingency by $1.8 million after a New York court dismissed Edwards Vacuum LLC’s indemnification lawsuit.
Azenta, Inc. executive Ephraim Starr, SVP, General Counsel & Secretary, purchased 335 shares of common stock on July 31, 2026 at $24.1676 per share. The shares were acquired under the Azenta, Inc. 2017 Employee Stock Purchase Plan, bringing his direct holdings to 68,728 shares, in a transaction exempt from Section 16(b) under Rule 16b-3(c).
Azenta, Inc. reported third-quarter fiscal 2026 results for the quarter ended June 30, 2026. Revenue from continuing operations was $161 million, up 12% year over year, with 9% organic growth. Sample Management Solutions revenue was $88 million and Multiomics revenue was $73 million, both growing double digits.
From continuing operations, Azenta recorded an operating loss of $4.2 million with a gross margin of 44.9%. Diluted EPS from continuing operations was ($0.03), while total diluted EPS, including discontinued B Medical Systems operations, was $0.05. On a non-GAAP basis, diluted EPS from continuing operations was $0.16, and Adjusted EBITDA was $18.5 million with an 11.4% margin. The company ended the quarter with $529 million in cash, cash equivalents, restricted cash and marketable securities and generated operating cash flow of $1 million (free cash flow of negative $5 million).
Under its 2025 share repurchase program, Azenta has bought back 2.3 million shares for $50.0 million, all retired. For full-year fiscal 2026, Azenta now expects reported revenue from continuing operations of $613–$618 million, organic revenue flat to up 1%, and Adjusted EBITDA of $59–$62 million.
Azenta, Inc. has completed the sale of its B Medical Systems business to Thelema S.à r.l. for a fixed purchase price of $63,000,000. The consideration consists of $28,000,000 in cash and a $35,000,000 short-term secured vendor loan from Azenta Germany GmbH to Thelema bearing 6.0% annual interest and maturing three months after funding.
Thelema’s obligations are secured by a first-priority pledge over 100% of B Medical’s equity, and the transaction is a related-party deal because Thelema is majority owned by B Medical’s CEO, who is also a Company vice president; Azenta’s audit committee reviewed and approved the arrangements. B Medical has been treated as a discontinued operation, and unaudited pro forma figures show net cash proceeds of $19,000,000, recognition of the $35,000,000 vendor loan receivable, removal of B Medical’s assets and liabilities, and a $41,464,000 reduction to retained earnings mainly from cumulative translation adjustments.
Azenta, Inc. director William L. Cornog made an indirect open-market purchase of 10,000 shares of common stock on May 18, 2026 at a weighted average price of $16.38 per share. The shares were bought through trusts he beneficially owns and controls, bringing his indirect holdings to 19,703 shares.